PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. Common dosages range from 100-500 mcg daily administered once daily.
What Is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. Also known as Spadin analog, TREK-1 blocker, it has been studied for its potential effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant. In the research community, PE-22-28 has gained attention for its distinctive profile.
How Does PE-22-28 Work?
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
This multi-pathway activity helps explain why PE-22-28 shows potential across several different applications.
What Does the Research Say About PE-22-28?
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended PE-22-28 Dosage?
Standard PE-22-28 dosing: 100-500 mcg daily, administered once daily via subcutaneous injection (proposed).
Half-life: 14-23 hours in rodents. Cycle length: 4-8 weeks.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →What Are the Side Effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
PE-22-28 is not fda-approved. investigational research peptide only.
Can You Stack PE-22-28 With Other Peptides?
Could theoretically pair with SSRIs for enhanced antidepressant effects through complementary serotonergic mechanisms.
What Is the Bottom Line on PE-22-28?
PE-22-28 is a Ion channel inhibitor peptide researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. Standard protocols use 100-500 mcg daily once daily for 4-8 weeks.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.